Citations

Clear

6273 citation(s) found for "To, Andrew".

The reservoir-wave approach to characterize pulmonary vascular-right ventricular interactions in humans
Andersen, Mads J. , Burrowes, Lindsay M. , Bouwmeester, J. Christopher , Belenkie, Israel, Borlaug, Barry A. , Tyberg, John V. , Ghimire, Anukul , Grant, Andrew D. , Fine, Nowell Mark , Borlaug, Barry A , Andersen, Mads Jønsson

Mayo Clinic

Journal of Applied Physiology | October 20, 2016 | Volume: 121 | Issue: 6 | Pages: 1348-1353

10.1152/japplphysiol.00697.2016 | PMID 27765845 Get It

Using the reservoir-wave approach (RWA) we previously characterized pulmonary vasculature mechanics in a normal canine model. We found reflected backward-traveling waves that decrease pressure and increase flow in the proximal pulmonary artery (PA). These waves decrease right ventricular (RV) afterload and facilitate RV ejection. With pathological alterations to the pulmonary vasculature, these waves may change and impact RV performance. Our objective in this study was to characterize PA wave reflection and the alterations in RV performance in cardiac patients, using the RWA. PA pressure, Doppler-flow velocity, and pulmonary arterial wedge pressure were measured in 11 patients with exertional dyspnea. The RWA was employed to analyze PA pressure and flow; wave intensity analysis characterized PA waves. Wave-related pressure was partitioned into two components: pressures due to forward-traveling and to backward-traveling waves. RV performance was assessed by examining the work done in raising reservoir pressure and that associated with the wave components of systolic PA pressure. Wave-related work, the mostly nonrecoverable energy expended by the RV to eject blood, tended to vary directly with mean PA pressure. Where PA pressures were lower, there were pressure-decreasing/flow-increasing backward waves that aided RV ejection. Where PA pressures were higher, there were pressure-increasing/flow-decreasing backward waves that impeded RV ejection. Pressure-increasing/flow-decreasing backward waves were responsible for systolic notches in the Doppler flow velocity profiles in patients with the highest PA pressure. Pulmonary hypertension is characterized by reflected waves that impede RV ejection and an increase in wave-related work. The RWA may facilitate the development of therapeutic strategies.
IC‐P‐074: Genome‐Wide Meta‐Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer’s Disease
Apostolova, Liana G. , Lin, Kuang, Allen, Mariet , Wang, Xue , Ertekin‐Taner, Nilüfer , Petersen, Ronald , Soares, Holly , Wang, Lisu, Qi, Zhenhao, He, Aiqing, Neuhaus, Isaac , Patel, Vishal , Faber, Kelley, Simmons, Andrew , Weiner, Michael W. , Nho, Kwangsik T. , Kim, Sungeun , Risacher, Shannon L. , Keohane, Aoife , Lunnon, Katie , Hodges, Angela , Burgess, Jeremy D. , Singh, Parul , Foroud, Tatiana , Lovestone, Simon , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2016.06.104 Get It

P3‐087: Gene Expression of ABCA7 Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus
Kim, Sungeun , Horgousluoglu, Emrin, Apostolova, Liana G. , Lin, Kuang , Allen, Mariet , Wang, Xue , Ertekin‐Taner, Nilüfer , Petersen, Ronald , Soares, Holly , Singh, Parul , Wang, Lisu, Qi, Zhenhao, He, Aiqing, Neuhaus, Isaac , Patel, Vishal , Faber, Kelley, Simmons, Andrew , Weiner, Michael W. , Nho, Kwangsik T. , Risacher, Shannon L. , Keohane, Aoife , Lunnon, Katie , Hodges, Angela , Burgess, Jeremy D. , Foroud, Tatiana , Lovestone, Simon , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2016.06.1746 Get It

IC‐P‐072: Gene Expression Of ABCA7 Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus
Kim, Sungeun , Horgousluoglu, Emrin, Apostolova, Liana G. , Lin, Kuang , Allen, Mariet , Wang, Xue , Ertekin‐Taner, Nilüfer , Petersen, Ronald , Soares, Holly , Singh, Parul , Wang, Lisu, Qi, Zhenhao, He, Aiqing, Neuhaus, Isaac , Patel, Vishal , Faber, Kelley, Simmons, Andrew , Weiner, Michael W. , Nho, Kwangsik T. , Risacher, Shannon L. , Keohane, Aoife , Lunnon, Katie , Hodges, Angela , Burgess, Jeremy D. , Foroud, Tatiana , Lovestone, Simon , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2016.06.102 Get It

O2‐06‐02: Genome‐Wide Meta‐Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease
Apostolova, Liana G. , Lin, Kuang, Allen, Mariet , Wang, Xue , Ertekin‐Taner, Nilüfer , Petersen, Ronald , Soares, Holly , Wang, Lisu, Qi, Zhenhao, He, Aiqing, Neuhaus, Isaac , Patel, Vishal , Faber, Kelley, Simmons, Andrew , Weiner, Michael W. , Nho, Kwangsik T. , Kim, Sungeun , Risacher, Shannon L. , Keohane, Aoife , Lunnon, Katie , Hodges, Angela , Burgess, Jeremy D. , Singh, Parul , Foroud, Tatiana , Lovestone, Simon , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.425 Get It

Immunomodulatory Role of Mesenchymal Stem Cell Therapy in Vascularized Composite Allotransplantation
Heyes, Richard , Iarocci, Andrew , Tchoukalova, Yourka D. , Tchoukalova, Yourka , Lott, David G , Lott, David G.

Mayo Clinic

Journal of Transplantation | October 16, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-10

10.1155/2016/6951693 | PMID 27822384 Get It

This review aims to summarize contemporary evidence of the in vitro and in vivo immunomodulatory effects of mesenchymal stem cells (MSCs) in promoting vascularized composite allotransplant (VCA) tolerance. An extensive literature review was performed to identify pertinent articles of merit. Prospective preclinical trials in mammal subjects receiving VCA (or skin allograft) with administration of MSCs were reviewed. Prospective clinical trials with intravascular delivery of MSCs in human populations undergoing solid organ transplant were also identified and reviewed. Sixteen preclinical studies are included. Eleven studies compared MSC monotherapy to no therapy; of these, ten reported improved graft survival, which was statistically significantly prolonged in eight. Eight studies analyzed allograft survival with MSC therapy as an adjunct to proven immunosuppressive regimens. In these studies, daily immunosuppression was transiently delivered and then stopped. In all studies, treatment-free graft survival was statistically significantly prolonged in animals that received MSC therapy. MSCs have been safely administered clinically and their use in renal transplant clinical trials provides evidence that they improve allograft transplant tolerance in clinical practice. There is potential for MSC induction therapy to overcome many of the obstacles to widespread VCA in clinical practice. Preclinical studies are needed before MSC-induced VCA tolerance becomes a clinical reality.
Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient
Murray, Michael J. , DeBlock, Heidi F., Erstad, Brian L. , Gray, Anthony, Jacobi, Judith , Jordan, Ché J., McGee, William T. , McManus, Claire, Meade, Maureen O. , Nix, Sean , Sands, M. Karen, Pino, Richard M. , Tescher, Ann, Arbour, Richard, Murray, Catherine Friederich, Mehta, Sangeeta , Patterson, Andrew J. , Rochwerg, Bram

Mayo Clinic

Critical Care Medicine | October 15, 2016 | Volume: 44 | Issue: 11 | Pages: 2079-2103

10.1097/ccm.0000000000002027 | PMID 27755068 Get It

Objective: To update the 2002 version of “Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient.” Design: A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of neuromuscular-blocking agents; a Grading of Recommendations Assessment, Development, and Evaluation expert; and a medical writer met via teleconference and three face-to-face meetings and communicated via e-mail to examine the evidence and develop these practice guidelines. Annually, all members completed conflict of interest statements; no conflicts were identified. This activity was funded by the Society for Critical Care Medicine, and no industry support was provided. Methods: Using the Grading of Recommendations Assessment, Development, and Evaluation system, the Grading of Recommendations Assessment, Development, and Evaluation expert on the Task Force created profiles for the evidence related to six of the 21 questions and assigned quality-of-evidence scores to these and the additional 15 questions for which insufficient evidence was available to create a profile. Task Force members reviewed this material and all available evidence and provided recommendations, suggestions, or good practice statements for these 21 questions. Results: The Task Force developed a single strong recommendation: we recommend scheduled eye care that includes lubricating drops or gel and eyelid closure for patients receiving continuous infusions of neuromuscular-blocking agents. The Task Force developed 10 weak recommendations. 1) We suggest that a neuromuscular-blocking agent be administered by continuous intravenous infusion early in the course of acute respiratory distress syndrome for patients with a Pa o 2 /F io 2 less than 150. 2) We suggest against the routine administration of an neuromuscular-blocking agents to mechanically ventilated patients with status asthmaticus. 3) We suggest a trial of a neuromuscular-blocking agents in life-threatening situations associated with profound hypoxemia, respiratory acidosis, or hemodynamic compromise. 4) We suggest that neuromuscular-blocking agents may be used to manage overt shivering in therapeutic hypothermia. 5) We suggest that peripheral nerve stimulation with train-of-four monitoring may be a useful tool for monitoring the depth of neuromuscular blockade but only if it is incorporated into a more inclusive assessment of the patient that includes clinical assessment. 6) We suggest against the use of peripheral nerve stimulation with train of four alone for monitoring the depth of neuromuscular blockade in patients receiving continuous infusion of neuromuscular-blocking agents. 7) We suggest that patients receiving a continuous infusion of neuromuscular-blocking agent receive a structured physiotherapy regimen. 8) We suggest that clinicians target a blood glucose level of less than 180 mg/dL in patients receiving neuromuscular-blocking agents. 9) We suggest that clinicians not use actual body weight and instead use a consistent weight (ideal body weight or adjusted body weight) when calculating neuromuscular-blocking agents doses for obese patients. 10) We suggest that neuromuscular-blocking agents be discontinued at the end of life or when life support is withdrawn. In situations in which evidence was lacking or insufficient and the study results were equivocal or optimal clinical practice varies, the Task Force made no recommendations for nine of the topics. 1) We make no recommendation as to whether neuromuscular blockade is beneficial or harmful when used in patients with acute brain injury and raised intracranial pressure. 2) We make no recommendation on the routine use of neuromuscular-blocking agents for patients undergoing therapeutic hypothermia following cardiac arrest. 3) We make no recommendation on the use of peripheral nerve stimulation to monitor degree of block in patients undergoing therapeutic hypothermia. 4) We make no recommendation on the use of neuromuscular blockade to improve the accuracy of intravascular-volume assessment in mechanically ventilated patients. 5) We make no recommendation concerning the use of electroencephalogram-derived parameters as a measure of sedation during continuous administration of neuromuscular-blocking agents. 6) We make no recommendation regarding nutritional requirements specific to patients receiving infusions of neuromuscular-blocking agents. 7) We make no recommendation concerning the use of one measure of consistent weight over another when calculating neuromuscular-blocking agent doses in obese patients. 8) We make no recommendation on the use of neuromuscular-blocking agents in pregnant patients. 9) We make no recommendation on which muscle group should be monitored in patients with myasthenia gravis receiving neuromuscular-blocking agents. Finally, in situations in which evidence was lacking or insufficient but expert consensus was unanimous, the Task Force developed six good practice statements. 1) If peripheral nerve stimulation is used, optimal clinical practice suggests that it should be done in conjunction with assessment of other clinical findings (e.g., triggering of the ventilator and degree of shivering) to assess the degree of neuromuscular blockade in patients undergoing therapeutic hypothermia. 2) Optimal clinical practice suggests that a protocol should include guidance on neuromuscular-blocking agent administration in patients undergoing therapeutic hypothermia. 3) Optimal clinical practice suggests that analgesic and sedative drugs should be used prior to and during neuromuscular blockade, with the goal of achieving deep sedation. 4) Optimal clinical practice suggests that clinicians at the bedside implement measure to attenuate the risk of unintended extubation in patients receiving neuromuscular-blocking agents. 5) Optimal clinical practice suggests that a reduced dose of an neuromuscular-blocking agent be used for patients with myasthenia gravis and that the dose should be based on peripheral nerve stimulation with train-of-four monitoring. 6) Optimal clinical practice suggests that neuromuscular-blocking agents be discontinued prior to the clinical determination of brain death.
Benchmarks for the interpretation of esophageal high‐resolution manometry
Keswani, Rajesh N. , Dunbar, Kerry B., Gawron, Andrew J. , Gyawali, C. Prakash , Katz, Philip O. , Katzka, David A. , Tatum, Roger P. , Pandolfino, John E. , Yadlapati, Rena , Kahrilas, Peter J. , Spechler, Stuart Jon , Gyawali, C P

Mayo Clinic

Neurogastroenterology & Motility | October 14, 2016 | Volume: 29 | Issue: 4 | Pages: No page available

10.1111/nmo.12971 | PMID 27739183 Get It

AbstractBackgroundCompetent interpretation of esophageal high‐resolution manometry (HRM) is integral to a quality study. Currently, methods to assess physician competency for the interpretation of esophageal HRM do not exist. The aim of this study was to use formal techniques to (i) develop an HRM interpretation exam, and (ii) establish minimum competence benchmarks for HRM interpretation skills at the trainee, physician interpreter, and master level.MethodsA total of 29 physicians from 8 academic centers participated in the study: 9 content experts separated into 2 study groups—expert test‐takers (n=7) and judges (n=2), and 20 HRM inexperienced trainees (“trainee test‐taker”; n=20). We designed the HRM interpretation exam based on expert consensus. Expert and trainee test‐takers (n=27) completed the exam. According to the modified Angoff method, the judges reviewed the test‐taker performance and established minimum competency cut scores for HRM interpretation skills.Key ResultsThe HRM interpretation exam consists of 22 HRM cases with 8 HRM interpretation skills per case: identification of pressure inversion point, hiatal hernia >3 cm, integrated relaxation pressure, distal contractile integral, distal latency, peristaltic integrity, pressurization pattern, and diagnosis. Based on the modified Angoff method, minimum cut scores for HRM interpretation skills at the trainee, physician interpreter, and master level ranged from 65–80%, 85–90% (with the exception of peristaltic integrity), and 90–95%, respectively.Conclusions & InferencesUsing a formal standard setting technique, we established minimum cut scores for eight HRM interpretation skills across interpreter levels. This examination and associated cut scores can be applied in clinical practice to judge competency.